• Mainstay Medical floated on Euronext Paris and the Enterprise Securities Market of the Irish Stock Exchange
  • Proceeds of the IPO will be used to conduct clinical trials and to obtain CE mark approval
  • Kempen & Co acted as Joint Global Coordinator and Joint Bookrunner and placed 41.6% of the shares with US investors